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Abstract
The lack of endogenous repair following spinal cord injury (SCI) accounts for the frequent
permanent deficits for which effective treatments are absent. Previously, we demonstrated that
low sulfated modified heparin mimetics (LS-mHeps) attenuate astrocytosis, suggesting they may
represent a novel therapeutic approach. mHeps are glycomolecules with structural similarities to
resident heparan sulfates (HS), which modulate cell signaling by both sequestering ligands, and
acting as cofactors in the formation of ligand–receptor complexes. To explore whether mHeps
can affect the myelination and neurite outgrowth necessary for repair after SCI, we created
lesioned or demyelinated neural cell co-cultures and exposed them with a panel of mHeps with
varying degrees and positions of their sulfate moieties. LS-mHep7 enhanced neurite outgrowth
and myelination, whereas highly sulfated mHeps (HS-mHeps) had attenuating effects. LS-mHeps
had no effects on myelination or neurite extension in developing, uninjured myelinating cultures,
suggesting they might exert their proregenerating effects by modulating or sequestering inhibi-
tory factors secreted after injury. To investigate this, we examined conditioned media from cul-
tures using chemokine arrays and conducted an unbiased proteomics approach by applying
TMT-LC/MS to mHep7 affinity purified conditioned media from these cultures. Multiple protein
factors reported to play a role in damage or repair mechanisms were identified, including
amyloid betaA4. Amyloid beta peptide (1–42) was validated as an important candidate by treat-
ing myelination cultures and shown to inhibit myelination. Thus, we propose that LS-mHeps
exert multiple beneficial effects on mechanisms supporting enhanced repair, and represent
novel candidates as therapeutics for CNS damage.
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1 | INTRODUCTION
Spinal cord injury (SCI) is predominantly caused by mechanical and
ischemic trauma to the spinal cord. As the CNS has limited
regenerative and repair capacity, any function loss is generally perma-
nent. The pathophysiology of SCI comprises both a primary and sec-
ondary cascade of injury mechanisms (Dumont et al., 2001). The
former causes axonal transection, cellular damage, and disruption of
the blood-brain barrier (BBB) while the latter leads to local neuronal
cell death and Wallerian degeneration, accompanied by the initiation
of an intense immune response. The CNS responds to these events by
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forming a glial scar rich in reactive astrocytes, myelin-associated inhib-
itors, microglia, macrophages, and meningeal fibroblasts which play a
major role in sequestering damaged tissue in a relatively impermeant
environment (Filous & Silver, 2016). Thus, any repair strategies for SCI
must consider multifactorial pathways including disruption of the scar,
promotion of axonal outgrowth, and remyelination.
Previously, we used a confrontation assay to study the effects of
astrocytosis, characterizing boundary formation, expression of GFAP,
and astrocyte hypertrophy (Lakatos, Franklin, & Barnett, 2000; Wilby
et al., 1999). We found that Schwann cells do not mingle with astro-
cytes whereas olfactory ensheathing cells (OECs) mingle well (Lakatos
et al., 2000). We identified heparin and FGFs as strong inducers of
boundary formation between astrocytes and OECs and concluded
that highly sulfated heparan sulfates (HS) secreted by Schwann cells
induced the astrocyte-Schwann cell boundary (Fairless, Frame, & Bar-
nett, 2005; Santos-Silva et al., 2007).
HS are linear sulfated polysaccharides that play an important role
in regulating many mammalian cellular processes. They exist as pro-
teoglycans (HSPG) in which two or three HS chains are attached to
core proteins at the cell surface, or extracellular matrix (ECM) pro-
teins. It is thought that the pattern, epimerization, and degree of sulfa-
tion is important in facilitating HS–ligand interactions, thereby
enabling HS to function as a key regulator of complex cell signaling
mechanisms in development, regulation of chemokine function, angio-
genesis, and blood coagulation, in both normal and disease states
(Bishop, Schuksz, & Esko, 2007; Changyaleket, Deliu, Chignalia, &
Feinstein, 2017; Cui, Freeman, Jacobson, & Small, 2013). To investi-
gate how HS sulfation characteristics influence astrocytosis, we
applied a panel of modified heparins (mHeps) which have been selec-
tively desulfated to the confrontation assay. We found that mHeps
with low sulfated (LS-) moieties could attenuate the astrocytic behav-
ior, whereas highly sulfated (HS-) mHeps induced a strong reactive
astrocyte response in culture (Higginson et al., 2012). This led us to
hypothesize that modifying the level of HS sulfation in the vicinity of
astrocytes might be a therapeutic approach to promoting one path-
way involved in CNS repair (O'Neill et al., 2017).
Although the above addresses effects on astrocytosis, if mHeps
are to be developed for treatment of the injured CNS, there is a need
to investigate possible effects on other neural cells. Therefore, we
studied the effect of mHeps on myelinating cultures generated from
dissociated spinal cord cells. These basic cultures are referred to as
myelinating cultures-development (MC-Dev). Second, an adaptation
of MC-Dev can be used to model aspects of CNS injury by cutting
mature cultures with a scalpel blade, generating a cell-free area char-
acterized by a persistent lack of neurite outgrowth. Over time, the
cell-free area becomes infiltrated with reactive astrocytes, and micro-
glia, as seen in animal models of CNS injury. These cultures are termed
MC-Inj (Boomkamp, Riehle, Wood, Olson, & Barnett, 2012). Finally,
mature myelinating cultures can be used to investigate demyelination
by treating them with anti-MOG antibody plus complement which
resulted in demyelination of axons (Elliott et al., 2012; MC-Demy).
When the panel of differentially sulfated mHeps was applied to these
three cultures types, we found that LS-mHeps not only attenuate
astrocytosis but also exert positive effects on neurite outgrowth and
remyelination suggesting these glycomolecules may be an important
novel therapeutic for CNS damage. Using tandem mass tag (TMT)
labelling and liquid chromatography–mass spectrometry (LC-MS) and
chemokine array of secreted factors from the two injury culture
models, we identified differences in heparin binding proteins (HBPs)
suggesting subtle difference in mechanisms.
2 | MATERIALS AND METHODS
2.1 | Astrocytes derived from neurospheres
Neurospheres (NS) were generated from the striata of 1-day-old
Sprague–Dawley (SD) rat using a method modified by Reynolds and
Weiss (1996) and differentiated into astrocytes as described in Soren-
sen, Moffat, Thomson, and Barnett (2008). Briefly, the tissue was
enzymatically dissociated and plated in NS medium (NSM) containing,
Dulbecco's Modified Eagle Medium/F12 (DMEM/F12, 1:1, DMEM
containing 4,500 mg/L glucose, Life Technologies, Carlsbad, CA),
enriched with 0.105% NaHCO3, L-glutamine, 5,000 IU/ml penicillin,
5 μg/ml streptomycin, 5.0 mM HEPES (all from Invitrogen, UK),
100 μg/ml apotransferrin, 25 μg/ml insulin, 60 μM putrescine, 20 μM
progesterone, and 30 μM sodium selenite, supplemented with
20 ng/ml of epithelial growth factor (EGF; all from Peprotech, UK).
The cell suspension was maintained until NS were formed. To gener-
ate astrocytes, the NS were triturated to produce smaller cell sphere
suspensions, transferred to 13 mm poly-L-lysine (PLL; 13 μg/ml,
Sigma) coated coverslips in a 24-well plate (Corning, UK) and incu-
bated for a further 5–7 days in vitro (DIV) at 37C in an atmosphere
of 7% CO2/93% air until a confluent monolayer formed. NS-derived
astrocytes were maintained in DMEM-1 g/ml glucose (Life Technolo-
gies) with 10% fetal bovine serum (Sigma, Poole, Dorset, UK) and
2 mM L-glutamine (Sigma).
2.2 | Modified heparins
Selectively chemically desulfated mHeps were prepared as described
previously (Higginson et al., 2012) and illustrated in Table 1. The com-
pounds described here had predominant repeating structures as fol-
lows (LS, low sulfated; HS, high sulfated): HS-mHep 1, IdoA(2S)-GlcNS
(6S); LS-mHep6, IdoA(2S)-GlcNAc; LS-mHep7, IdoA-GlcNS; LS-
mHep8, IdoA-GlcNAc.
2.3 | Myelinating spinal cord cultures (MC-Dev and
MC-Inj)
Generation of rat spinal cord mixed cell cultures (myelinating cultures
[MC]) was based on our previously described methods (Boomkamp
et al., 2012; Boomkamp, McGrath, Houslay, & Barnett, 2014; Soren-
sen et al., 2008). The spinal cord of E15.5 SD embryos were enzymati-
cally dissociated and the resulting cell suspension at 300,000 cells per
50 μl, were plated on top of the NS derived astrocytes on coverslips
in plating medium (PM) that contained 50% DMEM-1 g/ml glucose,
25% horse serum (Invitrogen), 25% HBSS (with Ca2+ and Mg2+, Life
Technologies) and 2 mM L-glutamine. Cells were left to adhere for
2 hr at 37C, then supplemented with 300 μl PM and 500 μl differen-
tiation medium which contained DMEM (4.5 g/ml glucose, Life
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Technologies), 10 ng/ml biotin (Sigma), 0.5% hormone mixture
(1 mg/ml apotransferrin, 20 mM putrescine, 4 μM progesterone, 6 μM
selenium (formulation based on N2 mix of [Bottenstein & Sato, 1979])
50 nM hydrocortisone, and 0.5 mg/ml insulin known as DM+, or DM
− if lacking insulin (all reagents from Sigma). Each 35 mm Petri dish
containing three myelinating culture coverslips was fed three times a
week by removing 400 μl of medium and adding 500 μl fresh DM+
for 12 DIV then DM− for the proceeding 12 DIV. Cultures were main-
tained for 24–35 DIV in an atmosphere of 7% CO2 at 37C and
referred to as MC-Dev. Over time these cultures elaborate myelinated
fibers interspaced with organized nodes of Ranvier (Sorensen et al.,
2008), with normal periodicity and compaction (Thomson et al., 2008).
To assess the effect of mHeps on developmental myelination, cultures
were treated at 13 DIV and 20 DIV (1 ng/ml). Furthermore, MC-Dev
cultures underwent a single treatment at 24 DIV to assess if mHeps
(1 ng/ml) had any effects on mature myelin. Following which both sets
of cultures were fixed and stained at 28 DIV. MC-Dev cultures were
treated with amyloid beta (Aβ)-peptide (1–42) rat (TOCRIS-2425) at
16, 19, and 21 DIV (1 μM) or combined with 100 ng/ml mHep7 during
feeding. The cultures were fixed and stained at 18, 20, 22, and 24 DIV
for myelin quantification (described below). Additionally, conditioned
media was collected for CytoTox 96® NonRadioactive Cytotoxicity
Assay (Promega G1780).
For generating MC-Inj, at 24 DIV myelinating cultures were cut
using a 11 mm single edge razor blade (WPI, Aston, UK) pressed
gently across the center of the coverslip. Details can be found in
Boomkamp et al., 2012, 2014. The cut created a focal cell-free area
(650 μm) with a decrease in neurite density and myelination levels
adjacent to it and very low numbers of neurites crossing the cut area
site, referred to as the lesion. Using these cultures lesion size, neurite
density and outgrowth, and myelination can be assessed using
immunocytochemistry.
MC-Inj responds appropriately to treatment with compounds
reported to be effective in animal models of CNS injury, corroborating
MC-Inj as a moderate throughput screen for CNS injury (Boomkamp
et al., 2012, 2014). The cultures were treated with each mHep at a
concentration of 1 ng/ml for a single treatment after 25 DIV and
allowed to recover for a further 5 DIV, cultures were then fixed and
stained as described below.
2.4 | Demyelinated cultures (MC-Demy)
To assess remyelination the myelinating cultures were set up and
maintained as described above. At 24 DIV, when many fibers are mye-
linated, the cultures were demyelinated by overnight incubation with
the Z2 antibody (100 ng/ml Hybridoma, a kind gift from Prof C Lining-
ton) which recognizes myelin oligodendrocyte glycoprotein (MOG)
and rabbit complement (100 μg/ml, Millipore) at 37C. The demyeli-
nated cultures were then washed with DM− to remove excess com-
plement and treated with the panel of mHeps at 1 ng/ml. At 30 DIV,
the cultures were fixed and stained as described below.
2.5 | Conditioned medium collection
To obtain medium conditioned by the various cultures, MC-Inj and
MC-Demy were set up. Conditioned media was collected after
25 DIV, for the cut conditioned medium (CCM) and demyelination
conditioned media (DCM); this was 24 hr after cultures had been cut
and demyelinated respectively. Uninjured culture conditioned medium
(UCM) was also collected from myelinating cultures at 25 DIV. CM
was also taken after treatment at 26 and 28 DIV (corresponding to
days 1 and 3 posttreatment). The CMs were added to MC-Dev at
16, 19, and 21 DIV. CM was diluted 1:4 with DM− or combined with
1 ng/ml mHep6. At 24 DIV, the cultures were fixed and stained as
described below.
2.6 | Cytokine array screen
Conditioned medium from each type of MC was collected as
described above and 1.5 ml was assayed in a Proteome Profiler Rat XL
Cytokine Array (R&D Systems, ARY030) using the manufacturer's
protocol. The array simultaneously detects levels of 79 rat cytokines,
chemokines, growth factors, and other soluble proteins (see https://
www.rndsystems.com/products/proteome-profiler-rat-xl-cytokine-
array_ary0300. Comparisons of CCM and DCM were made to UCM,
using semi-quantitative densitometry analysis on Total Lab Quant
Software (TotaLab Limited). Using the circle tool each dot was individ-
ually quantified with duplicates averaged and the integrated density
values compared.
TABLE 1 Library of modified heparins (mHeps): List of mHeps showing their predominant disaccharide repeat along with the corresponding
chemical modification; (a) depicts fisher projection of commercial heparin; and (b) schematic of hexose sugar ring backbone with the carbons
labeled
mHep Disaccharide repeat Modification
1 IdoA(2S)-GlcNS(6S) Heparin control
6 IdoA(2S)-GlcNAc 6-O-desulfation/N-acetlyation
7 IdoA-GlcNS 2-O-desulfation /6-O-desulfation
8 IdoA-GlcNAc 2-O-desulfation /6-O-desulfation /N-acetlyation
(a) (b)
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2.7 | Oligodendrocyte progenitor cell culture
Oligodendrocyte progenitor cells (OPC) were isolated from cortical
astrocyte monolayers generated from postnatal day 1 (P1) SD pups by
differential adhesion as previously described (Miron et al., 2013;
Noble & Murray, 1984). OPCs were maintained in serum-free DMEM-
BS (adapted from Bottenstein & Sato, 1979) containing 0.5 mg/ml
insulin in 10 mM HCL (Sigma, UK), glutamine (100 mM, Sigma), human
transferrin (0.1 mg/ml, Sigma) and gentamycin (100 mg/ml, Sigma),
supplemented with the growth factors; fibroblast growth factor (FGF-
2) at 10 ng/ml and platelet derived growth factor (PDGF) at 2 ng/ml
(both Peprotech, UK). The isolated OPCs were plated on poly-L-lysine
(PLL, 13 μg/ml, Sigma) coated glass coverslips (VWR) in a 24-well
plate at a density of 5,000 cells in 50 μl drop and allowed to attach.
They were maintained in DMEM-BS containing PDGFα and FGF2 for
5 days and then switched to DMEM-BS lacking growth factors and
with or without mHeps at a concentration of 1 ng/ml. Cultures were
used for proliferation, morphology, and differentiation assays.
2.8 | Nanofibres
OPCs were seeded onto PLL coated nanofiber culture inserts
(Nanofiber Solutions TM) at a density of 25,000 cells in DMEM-BS
containing PDGFα and FGF2 and incubated for 5 DIV. The OPC
medium was then switched to DMEM-BS containing mHeps at
1 ng/ml for 7 DIV. Purified OPCs sheath length was quantified after
mHep treatment by measuring a single internode (PLP+ process) per
cell, from cell body to outmost internode and cell size by measuring
the surface area of each cell in ImageJ.
2.9 | Immunocytochemistry
MC were fixed with 4% paraformaldehyde (4% PFA, Sigma) for
20 min at room temperature (RT) and permeabilized with 0.2% Triton
X-100 (Sigma) at RT for 15 min, blocked with PBS with 0.2% porcine
gelatin (Sigma) prior to addition of primary antibodies for 1 hr at
RT. For extracellular labeling, the cultures were incubated with pri-
mary antibodies for 20 min at RT. Oligodendrocyte lineage cells were
visualized with the O4 antibody (1:1, mouse IgM hybridoma: Som-
mer & Schachner, 1981). Cells were washed, incubated with the
appropriate secondary Alexa fluorophore-conjugated antibody (1:500,
Life Technologies) for 20 min at RT and fixed in ice-cold methanol for
15 min at −4C. For co-labeling with intracellular antibodies, cells
were incubated with primary antibodies, diluted in blocking buffer
(containing PBS with 0.1% Triton X-100 and 0.2% porcine gelatin) for
45 min at RT followed by the appropriate secondary Alexa
fluorophore-conjugated antibodies for 45 min at RT. The cells were
washed and mounted in Vectashield (Vector Laboratories, Peterbor-
ough, UK).
For intracellular labeling alone, the cultures were fixed in 4% PFA
for 20 min at RT followed by washes in PBS and permeabilization in
0.2% Triton-X100 for 15 min at RT. The primary antibodies were
added, diluted in blocking buffer, and the cells incubated for 45 min at
RT. Mature myelin (PLP) was visualized using AA3 antibody (1:100,
anti-rat; hybridoma supernatant, Yamamura, Konola, Wekerle, & Lees,
1991), Neurofilament was detected using SMI31 (mouse IgG1,
1:1500, BioLegend). After washing, the cultures were incubated with
the appropriate secondary antibodies at RT for 45 min. The cells were
washed in PBS followed by dH2O, mounted in Vectashield (Vector
Laboratories, Peterborough, UK).
2.10 | EdU cell proliferation assay
For proliferation studies OPCs were maintained for only 2 days in
DMEM-BS containing PDGFα and FGF2. The cells were then
switched into DMEM-BS lacking growth factors for 24 hr (except for
the PDGF/FGF condition) before treatment with mHeps, along with
immediate incubation with 10 mM of 5-ethynyl-20-deoxyuridine (EdU)
for 18 hr. EdU detection was performed using Click-iT EdU imaging
kit (C10084, Invitrogen) per manufacturer's instructions. The OPCs
were then immunolabeled with Olig2 (Rabbit polyclonal, 1:500, Milli-
pore, UK) following which cultures were washed and mounted as pre-
viously described.
2.11 | Microscopy and image analysis
Cells were imaged using Olympus BX51 or LAS AF Leica DM4000 B
fluorescence microscopes. For quantitative analysis of injury, neurite
density, myelination, and neurite outgrowth, the entire lesion site
were imaged adjacent (0–670 μm from the lesion edge) and the actual
injury site with each condition being blinded to the experimenter. Sim-
ilarly, for the MC-Dev and MC-Demy quantification of neurite density
and myelination, each condition was blinded to the experimenter and
standardized random sampling was performed. For neurite density,
myelination, and neurite outgrowth studies images were taken at 10×
magnification with 20 images per coverslip. Cell counting analysis was
made for OPCs and OLs respectively at 10× and 20× magnifications
with 10 images per coverslip. The cells of interest were counted per
field of view and divided by the total number of DAPI-positive cells.
2.12 | Myelination and OPC/oligodendrocyte
(OL) quantification
Quantification was carried out using CellProfiler Image Analysis soft-
ware (Broad Institute) (Carpenter et al., 2006; Lindner et al., 2015).
For neurite density, the threshold level pixel value for SMI31 immuno-
reactivity (IR) was divided by the total number of pixels. The percent-
age of myelinated axons (PLP) was measured using CellProfiler, which
uses pattern recognition software to distinguish between linear mye-
linated internodes and oligodendrocyte cell bodies. In this manner, we
track the co-expression of myelin sheaths (PLP) and axons (SMI31)
and calculate this percentage of myelinated fibers. All experiments
were carried out at least three times in duplicate. For OL quantifica-
tion images adjacent to the lesion were used and OL cells were calcu-
lated using a Cellprofiler pipeline which counts the presence of PLP+
cell bodies overlapping DAPI nuclei. OPC/OL cultured on nanofibers
were analyzed for cell size and myelin internode length. Both were
calculated using ImageJ software. Two measurements per cell were
taken from the cell body to the outmost myelin internode 20 cells
were used per image selected at random. The cell size was defined by
the green (PLP+) pixel threshold compared to the total pixel intensity
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and individual cells were marked with the region of interest (ROI) tool
to allow single cell analysis. All CellProfiler pipelines used in this study
are available at https://github.com/muecs/cp.
2.13 | Neurite outgrowth and lesion size
quantification
Ten images of the cut in the MC-Inj were collected using random sam-
pling. Neurite outgrowth was defined as a SMI31 positive projection
which enters and crosses the lesion site. In each image, the number of
neurites which cross the lesion site was counted. Any area around the
lesion that appeared uninjured was excluded from analysis. The num-
ber of neurites per image was averaged across the lesion and termed
neurite outgrowth per field of view. Using the same images, the width
of the lesion was calculated using ImageJ at 10 fields of view per
lesion, averaged and termed lesion width (μm).
2.14 | HBPs pull down and mass spectroscopy
analysis
CCM, DCM, and UCM were affinity purified on an mHep7 column. To
make the column a commercial HiTrap NHS-activated HP column
(1 ml, GE Healthcare) was washed extensively with ddH2O (20 ml)
and 10 mg (1 ml) of mHep7 was introduced onto the column and
allowed to react at 15C for 2 hr. Any unbound mHep7 was washed
off the column with ddH2O (20 ml) and a small soluble amine (5% eth-
anolamine in ddH2O, Sigma) was added to react with any remaining
N-hydroxysuccinimide (NHS) groups at 15C for 2 hr. The column was
washed with PBS (pH 7.5, 20 ml) and ready for use to capture mHep7
binding proteins. Six milliliters of the different CM was run down the
column with a peristaltic pump, following the manufacturer's instruc-
tions. Binding buffer and elution buffer was 10 mM sodium phos-
phate, pH 7 and 10 mM sodium phosphate, 1 M NaCl pH 7,
respectively (Both from VWR). The eluted HBPs were desalted and
concentrated using Amicon Ultra-15 centrifugal device (3K, 15 ml;
Millipore, UK). The proteins were digested with trypsin, using the
FASP protocol (Wisniewski, Zougman, Nagaraj, & Mann, 2009) and
analyzed by LC–MS using an Orbitrap Elite MS (Thermo Scientific) as
described previously (Akpunarlieva et al., 2017). Protein identifications
were assigned using the Matrix Science MascotDaemon server
(Mascot) search engine to interrogate protein sequences in the Uni-
Prot database RAT genome, allowing a mass tolerance of 10 ppm for
the precursor and 0.6 Da for MS/MS matching.
To obtain quantitative data, UCM, CCM, and DCM were also ana-
lyzed by tandem mass tag (TMT) labeling and liquid chromatography–
mass spectrometry (LC–MS). The samples were digested with trypsin
to generate peptides that were differentially labeled with multiplex
tandem mass tags as previously described (Bilic et al., 2018). Samples
were then mixed and analyzed by LC–MS. The TMT plates are six-plex
to enable multiplex analysis and the resulting peptides, covalently
labeled with TMT tags, were solubilized in 2% acetonitrile with 0.1%
trifluroacetic acid and fractionated on a nanoflow uHPLC system
(Thermo RSLCnano) before online analysis by electrospray ionization
(ESI) mass spectrometry on an Orbitrap Elite mass spectrometer.
Peptide separation was performed on a Pepmap C18 reversed phase
column (LC Packings). The output from the LC–MS/MS was deconvo-
luted using ProteomeDiscoverer software, with advice from bioinfor-
maticians at Glasgow Polyomics, and the relative change in
abundance of proteins between samples for comparison was deter-
mined, with statistical significance assessed by analysis of variance
between replicates using Minitab. Any value with a Mascot score of
greater than 70 was considered significant and those with Mascot
scores below 20 were discounted.
2.15 | Amyloid beta (Aβ) (1–42) and (1–40) ELISAs
MC-Demy cultures were treated with mHep7 (1 ng/ml) and media col-
lected at 26 and 28DIV (equating to days 1 and 3 posttreatment, respec-
tively). This CM and mHep7 eluate described above were tested using
amyloid beta peptide 1–42 and 1–40 ELISAs (Thermofisher, KHB3441/
KHB3481) as per manufacturer's description.
2.16 | Statistical analysis
GraphPad Prism software was used for data presentation and statistical
testing. For simple comparison paired Student's t test was employed to
determine statistical significance. For multiple condition comparisons, a
one-way repeated measures ANOVA test was employed to data sets fol-
lowed by Dunnett's multi-comparison test or Holm–Sidak post hoc cor-
rection to calculate potential significant difference. Asterisks are used to
represent significantly less than *p < .05, **p < .01, ***p < .001 and
inserted onto graphed data. All errors are depicted as standard errors of
the mean (SEM). A minimum of three technical repeats/experiment and
at least three biological (n) repeats were made. Gene Ontology term
enrichment analysis was performed in R, using TopGO (Alexa &
Rahnenfuhrer, 2016). As a Gene Ontology database, we used the GO
term from UniProt. To correct for multi-testing, we multiply the p value
by the amount of statistical test thatwas performed.
3 | RESULTS
3.1 | Selectively desulfated mHeps promote neurite
outgrowth and myelination in myelinating culture-
injured (MC-Inj)
The effects of a number of selectively desulfated mHeps (Higginson
et al., 2012; O'Neill et al., 2017) on neurite density, myelination, neurite
outgrowth, and lesion size following injury were assessed using the
MC-Inj model. High power images of demyelination after injury and the
subsequent myelination after 5 days can be seen in Figure 1a,b.
Figure 1c–g shows representative images of myelination adjacent to the
lesion in cut control (c) and mHep treated (d–g) MC-Inj. It can be seen
that the percentage of myelinated fibers was significantly higher after
treatment with the low- or de-sulfated mHeps6-8 increasing to 8–10%
from 5% in untreated control (p = .0017, <.0001, and .0001 for mHep6,
7, and 8, respectively), but treatment with HS-mHep1 resulted in a
decreasing trend to 2.5% although this appears nonsignificant (Figure 1d,
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FIGURE 1 LS-mHep promote myelination and neurite outgrowth (a,b) High power images of demyelination adjacent to the lesion after injury and
the subsequent myelination occurring after 5 days. Representative images of MC-Inj of a control cut (c) and after a single treatment with LS-
mHep6-8 (e–g) showing a promotion of myelination adjacent to the lesion which is adjacent and just out of view in the images. In contrast, the
HS-mHep1 showed a nonsignificant decrease in the levels of myelination (d). Quantification of the images are shown in h (p = .0017, p < .0001
and p = .0001 for mHep6, 7 and 8 respectively). Only mHep6 significantly promoted neurite density adjacent to the lesion when compared to
control cultures (p = .0127) (i). Representative images of the lesion after cutting with a scalpel blade in MC-Inj (j), and after HS-mHep1 treatment
showing no effect on neurite outgrowth (k). Significant neurite outgrowth across the lesion was seen after treatment with LS-mHep6-8 compared
to control untreated cultures (p = .0172, p < .0001 and p = .0029 for mHep6, 7, and 8, respectively) (l–o). Representative image of lesion size is
shown in (j–n) identified by dashed line. An increase in lesion width following treatment with HS-mHep1 (564.5 μm) was seen, compared to the
control lesion (400 μm p = .0026). LS-mHep6-8 had no effect on lesion width (p). Statistical test used was one-way ANOVA with post hoc
Dunnett's multi-comparison correction. Scale bar, 25 μm and 50 μm, error bars SEM, SMI31-red, PLP-green (n = 6; technical replicates = 3)
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g, quantification in panel h). Neurite density was analyzed adjacent to the
injury site and a significant increase (p = .0127) was observed after treat-
ment with LS-mHep6 compared to the untreated control, whereas the
other mHeps1, 7, and 8 had no significant effect on neurite density
(Figure 1i). Figure 1j–n show representative images of neurites crossing
the lesion and the lesion size in control and treated cultures. Quantifica-
tion of the average number of neurites crossing the lesion is shown in
Figure 1o. The LS-mHeps 6–8, all significantly promoted neurite out-
growth across the lesion compared to the untreated control (p = .0172,
<.0001, and .0029 for mHep6, 7, and 8, respectively). The HS-mHep1
did not promote neurite outgrowth after treatment, with neurite num-
bers being similar to the untreated control (~3 neurites/field of view).
Finally, the width of the lesion was quantified after mHep treatment
(Figure 1p). HS-mHep1 treatment resulted in a significant increase in
lesion size (564  27.5 μm, p = .0026) compared to the untreated con-
trol (400  20.0 μm, Figure 1j,k, and p). In contrast, the LS-mHeps6–8,
did not significantly affect the lesion size, with average lesion sizes being,
315.2  46.8 μm (mHep6), 405  48.6 μm (mHep7), and
317  56.2 μm (mHep8).
3.2 | LS-mHeps promote oligodendrocyte process
extension
To determine the effect of the mHeps directly on OPCs, we treated
purified OPCs with 1 ng/ml of mHeps. First, we established that OPC
proliferation was unaffected by any mHep treatment when compared
to DMEM-BS control, and PDGF/FGF2 treatment, a growth factor
cocktail known to promote OPC proliferation (p = .0032; Figure 2a–
c). Representative images of the control and PDGF/FGF treated OPCs
are shown in Figure 2a,b, respectively. HS-mHep1 treatment induced
a significant decrease in OL numbers adjacent to the lesion compared
to the untreated control (Figure 2d–f; p = .0336). Conversely, LS-
mHep6 and 7 treatment resulted in a significant increase in the num-
ber of OLs adjacent to the lesion site compared to control (Figure 2d–
f; p = .0133 and .0002).
To investigate whether mHeps directly affect OPC process wrap-
ping we used nanofibers which allow the study of ensheathment in
the absence of dynamic neuronal signaling (Lee et al., 2012). The OL
sheath length in DMEM-BS alone (control) averaged 166.6  20.4 μm
with the growth factor control (PDGF/FGF) cell size only reaching
87.3  31.2 μm (Figure 2g–l). HS-mHep1 had no significant effect on
the sheath length with the average length reaching 150.6  57.9 μm
(Figure 2h–l). Similarly, the LS-mHep7 had no significant effect on the
sheath length with average lengths measuring 196.9  60.2 μm
(Figure 2j–l). The cell area of OLs was significantly increased following
treatment with LS-mHep7 (289.2  49.8 μm2, p < .0001) compared
to control (139  16.9 μm2; Figure 2j,k). Treatment with LS-mHep6
and 8 did not affect cell area (157.9  41.9 and 141.9  36.9 μm2,
respectively), however, HS-mHep1 treatment caused a nonsignificant
decrease in the overall cell area (79.7  8.3 μm2; Figure 2h),
Moreover, LS-mHep6 and 8 treatment induced a significant increase
in the OL sheath length compared to control with an average length
of 298.6  84.3 μm and 317.4  66.7 μm, respectively (Figure 2i–l;
p = .0001 for both).
3.3 | mHep treatments have no effect on
myelination levels in MC-Dev
Rat myelinating cultures (MC-Dev) were treated with mHeps1, 6, and
7 (1 ng/ml) after 13 DIV or 24 DIV, fixed and stained at 28 DIV and
the percentage of myelination and neurite density within the cultures
quantified. Figure 3a–d illustrates representative images of control
and treated cultures after mHeps were added from 13 DIV while
Figure 3g–j show their effects when added from 24 DIV. Myelination
and neurite density were quantified and shown in Figure 3e–k and f–l,
respectively. It can be seen that mHep treatments did not significantly
affect either myelination levels or neurite density in MC-Dev when
added from 13 DIV compared to untreated control. In contrast, when
treatment occurred at 24 DIV, once more fibers were myelinated, it
was seen that the addition of mHep1 and mHep7 resulted in a signifi-
cant decrease in myelination when compared to untreated controls
(Figure 3k; p = .0033 and .0163, respectively), although neurite den-
sity was not affected (Figure 3l).
3.4 | LS-mHep treatment enhances CNS
remyelination
Because the developmental myelination in MC-Dev was essentially
unaffected by treatment with mHeps, we hypothesized that the injury
environment produced by MC-Inj may be essential to their effective-
ness in promoting myelination. We propose that similar effects would
be seen in a different CNS injury environment. To address this, we
used MC-Demy, in which MC-Dev cultures were demyelinated with
complement and anti-MOG antibody followed by a single treatment
with mHeps (1 ng/ml), and maintained until 30 DIV, followed by stain-
ing for PLP and SMI31 to visualize myelination and neurites respec-
tively. Figure 4a,b shows high power images of the loss of myelin
sheaths immediately after demyelination (Demy0) and the subsequent
remyelination after 5 days. Figure 4c–h shows representative images
and Figure 4i,j shows the quantification of myelination and neurite
density respectively. It can be seen that LS-mHeps treatment
increased the percentage of myelinated fibers by 70–80% compared
to a nontreated demyelinated culture on day 5 referred to as Demy5,
without affecting neurite density (p = .0002, .0004, and .0002 for
mHep6, 7, and 8, respectively). This suggests that the LS-mHeps
enhance remyelination in this injury environment, absent of any toxic
effects on neural cells.
3.5 | Conditioned medium collected from MC-Inj
(CCM) reduces CNS myelination
Since we only observed effects on myelination using LS-mHeps in
MC-Dev after a cut or antibody-mediated demyelination, we hypothe-
sized that mHeps exert their effects by modulating factors released by
injury. To address this, we collected conditioned medium from MC-Inj
(CCM; 1 in 4 dilution) and added it to MC-Dev at 16, 19, and 21 DIV,
fixing and staining the cultures at 18, 20, 22, and 24 DIV with anti-
PLP and the SMI31 antibody. Treatment with CCM resulted in a 33%
reduction in myelination compared to control at 24 DIV (Figure 5a)
suggesting the lesion in MC-Inj releases factors which are inhibitory
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FIGURE 2 LS-mHeps do not affect OPC proliferation but promote the number of OL adjacent to the lesion and process extension on nanofibers.
(a–c) mHep treatment had no effect on the proliferation of OPCs. a and b are representative images fluorescently labeled with DAPI-blue and
EdU-red of PDGF/FGF treated and control OPCs, respectively. Quantification of proliferation was determined by percentage of EdU positive
cells which demonstrated no difference between control and mHep treated OPCs (c). (d–f ) LS-mHep6 and 7 treatment caused an increase in the
number of OLs adjacent to the lesion (p = .0133 and p = .0002, respectively). (d) Microscope image stained for PLP (green) and SMI-31 (red) at
lesion edge of MC-Inj. (e) Same image quantified for PLP-IR (OL) after LS-mHep treatment. In contrast, HS-mHep1 treated cultures showed a
significant decrease in the number of OLs compared to control cultures (p = .0336). Representative images of PLP stained OPCs plated on
nanofibers in the presence of DMEM-BS (g), HS-mHep1 (h), LS-mHep6 (i), and LS-mHep7 (j). (k) Quantification of cell area demonstrated that LS-
mHep7 treatment resulted in an increase in the OL cell size, compared to the untreated control (p < .0001). (l) Quantification of myelin sheath
length demonstrated that LS-mHep6 and 8 treatments statistically promoted sheath length compared to controls (p = .0001 for both). As
expected GF treated OPCs had a reduced OL cell size (p = .0005) with limited process extension along the nanofibers (k, l). Statistical test used
was one-way ANOVA with post hoc Dunnett's multi-comparison correction. Scale bars, 100 μm and 25 μm, error bars SEM (n = 4; technical
replicates = 3)
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to CNS myelination. This is unlikely to be nonspecific toxicity as neur-
ite density remains unaffected (Figure 5b). Co-treatment with CCM
and LS-mHep6 indicated a trend towards the rescue of CCM-induced
hypomyelination (assessed by the level of myelination at 24DIV),
though this difference did not reach statistical significance
(p = .1163). These data suggest that the LS-mHep6 may modulate the
properties of proposed heparin binding factors that are induced by
injury (Figure 5k,l). Representative images are seen in Figure 5c–j.
FIGURE 3 2-O-sulfated mHeps had no effect on the development of myelination but mHep1 and the N-sulfated isoform affected myelinated
fibers. (a–d) Representative images of MC-Dev control or mHep (1 ng/ml added at 13 and 20 DIV) treated cultures showing myelinated fibers,
SMI31-red and PLP-green. (e) Quantification of myelination relative to the untreated control showing no significant difference in myelination
levels after mHep treatment. (f ) Neurite density was also unaltered by mHep treatment. (g–j) Representative images of MC-Dev control or mHep
(1 ng/ml added at 24 DIV) treated cultures. Quantification of myelination (k) demonstrated a reduction in myelination levels post-HS-mHep1
(p = .0033) and LS-mHep7 (p = .0163) treatments on the mature cultures. While neurite density remained unchanged (l). Scale bars 100 μm, error
bars SEM (n = 4; technical replicates = 3)
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3.6 | Secreted chemokine/cytokine profile is altered
after MC-Inj and MC-Demy
As a first step to identifying molecules involved in the effects of
mHeps described above, we took a candidate approach, reasoning
that chemokines and cytokines which bind heparin/HS could be impli-
cated. To identify specific chemokines and cytokines released in CCM
and DCM, we conducted a protein array of conditioned media (see
methods for details of array). Figure 6b–d illustrates the changes in
the secreted cytokines standardized to the UCM. Green and red
circles indicate only these factors that had a >2-fold increase
or < 0.8-fold decrease, respectively. Several factors were upregulated
in both CCM and DCM including CXCL2, CXCL5, and CCL5 (average
fold increase of 8.5/16.4, 4.9/6.4, and 3.5/6.6 for CCM and DCM,
respectively). Striking differences in secreted cytokine profiles were
also seen between the two injuries. Many immune-associated factors
including CCL3, IL-1α, IL-1β, IL-6, and TNF-α were increased in DCM
by an average fold change of 9.1, 6.3, 8.9, 3.3, and 4.5, respectively.
Interestingly, the same proteins showed no change in CCM, apart
from IL-1α and IL-1β, for which a decrease was observed (0.4 and 0.6,
FIGURE 4 LS-mHeps have significant effects on remyelination in MC-Demy. Myelinating cultures were allowed to mature until 24 DIV at which
point they were demyelinated via overnight incubation with the anti-MOG specific antibody Z2 (100 ng/ml) and rabbit complement (100 μg/ml).
Treatment occurred at 25 DIV (1 ng/ml) and then cultures were allowed to recover till 30 DIV, at which point they were immunolabeled with
SMI31 (red, neurites) and AA3 (green, myelin). (a,b) High power images showing the loss of myelin immediately after demyelination (Demy0) and
the remyelination after 5 days. (c–h) Representative images of MC-Demy treated with anti-MOG and complement on 25 DIV (d) and 30 DIV
(e) and treated with the mHeps (f–h). (i) Quantification of myelination showing treatment with mHeps resulted in an 87, 71, and 81% increase in
remyelination compared to the nontreated demyelinated control culture on day 5 (Demy5) for LS-mHeps6, 7, and 8 respectively (one-way
ANOVA with Holm–Sidak multiple comparison, p = .0002, .0004, and .0002). (j) Quantification of neurite density showed no change in density
with treatment implying no adverse toxic effects on the cultures. Scale bars 25 and 100 μm, error bars SEM (n = 4; technical replicates = 3)
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FIGURE 5 Cut conditionedmedium (CCM) significantly reduces developmental myelination, which is partially overcome by LS-mHeps. CCMwas
collected fromMC-Inj at 25DIV and used to treatMC-Dev cultures at 16, 19, and 21DIV (1 in 4 dilution). (c–j) Representative images of control and
CCM treated cultures, immunolabeledwith SMI31-red and PLP-green. (a,b) Quantification ofmyelination and neurite density over time after CCM
treatment showing no difference in the development ofmyelination between CCM treated and control cultures at 18, 20, and 22DIV. However, at
24DIV, there was a significant 33% reduction inmyelination of the CCM treated cultures compared to the control (p = .0031). (k,l) Quantification of
myelination and neurite density ofMC-Dev after a combined treatment of CCMand LS-mHep6 showed an increase in the number ofmyelinated fibers
so as to be nonstatistically different from the untreated control. Quantification of neurite density after treatmentwith CCMshowed no adverse effects
on neurites (one-way ANOVAwithDunnett multiple comparison). Scale bars 100 μm, error bars SEM (n = 3; technical replicates = 3)
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respectively). The proteins which were exclusively increased in CCM
were trophic factors including HGF, CNTF, Flt-3 ligand, and prolactin,
which displayed corresponding average fold changes of 3.9, 2.5, 2.6,
and 2.2. Comparing the data set as a whole we observed a significant
difference in the proteome profiler between the UCM and the
CCM/DCM (p = .0008 and .0004, respectively), suggesting a clear
shift in the secretome postinjury. Additionally, there was a significant
difference between the CCM and DCM identified in this array
(p = .0047), suggesting some level of injury-type specificity in the
CNS injury secretome.
3.7 | Mass spectrometry analysis of conditioned
medium from MC-Inj and MC-Demy
As an unbiased approach to identify molecules involved in the effects
of mHeps, we used affinity proteomics to explore directly bound pro-
teins that might be mediating the biological responses. To assess
which proteins present in the UCM, CCM, and DCM interact with LS-
mHep7, we performed a protein pull-down using an mHep7 affinity
column, followed by mass spectroscopy (MS) analysis on the eluted
samples. Number and distribution of specific and shared proteins can
be seen in the Venn Diagram (Figure 7a). Overall 431 proteins were
identified. CCM contained 143 unique proteins; DCM contained 108.
About 33 proteins were shared between CCM and DCM whereas
47 were specific to UCM. To validate the overall data, we performed
gene ontology analysis and initially determined the GO enrichment
E-value for the entire data set including all three intersections. HBPs
(GO:0008201) was the highest enriched term with an E-value of 5.4 e
−15, validating the methodology for pulling down proteins related to
heparin binding. Due to the nonquantitative nature, and therefore the
inability to make direct comparisons between samples, we carried out
TMT LC–MS analysis of the conditioned media.
3.8 | TMT–LC/MS analysis of conditioned medium
from MC-Inj and MC-Demy
TMT labeling allows the comparison of peptide levels between multi-
ple samples in a single LC–MS run. This multiplexing circumvents
problems with reproducibility in serial LC–MS analyses and allows rel-
ative quantitation in comparison to control samples. We were able to
compare the abundances of LS-mHep7 binding proteins present in
each of the CM. Protein levels in the injury CM were standardized to
FIGURE 6 Differences in chemokine/cytokine secretion profile after CNS injury. Cut conditioned media (CCM), demyelinated conditioned medium
(DCM), and control conditioned medium (UCM) were collected from MC-Inj, MC-Demy, and MC-Dev, respectively, on 25 DIV and the cytokine
profile assessed using a rat cytokine array. (a) Dot blots of the cytokine arrays for each of the conditioned media. (b–d) Tables illustrating the fold
changes with (SD) of expression changes in both CCM (b), DCM (c), and CCM/DCM (d) compared to UCM, the green and red spheres indicate
>2-fold increase and <0.8-fold decrease respectively (n = 3; technical replicates = 2)
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UCM allowing us to state a fold change (FC) after injury. Figure 7b
shows LS-mHep7 binding proteins with a fold change of >1.3 (red) or
<0.8 (blue) after injury and a Mascot score of >29 (higher Mascot
scores indicate increased confidence in the protein hits). There were
8 mHep7 binding proteins that had elevated abundances after both
MC-Inj and MC-Demy represented in the plots by large red symbols
(Figure 7b). These include growth hormone releasing hormone recep-
tor which had a massive increase of 327.00 and 136.50 for CCM and
DCM, respectively (although with a weak Mascot score of 30). Addi-
tionally, amyloid beta A4 protein (APP) increased 5.7- and 2.0-fold in
CCM and DCM (Table 2c). There were nine proteins which demon-
strated an elevated abundance uniquely in the CCM (Table 2a) includ-
ing apolipoprotein D, clusterin, calsyntenin-3, and alpha-
2-macroglobulin which showed corresponding fold changes of 2.0,
1.9, 1.8, and 1.6 compared to UCM. There were 23 proteins which
demonstrated elevated levels uniquely in the DCM after binding to
mHep7 (Table 2b). These proteins are diverse in both structure and
function from the large lipid transporter apolipoprotein B-100 (4.57
FC), ECM glycoproteins thrombospondin (4.07 FC) and tenascin C
(1.44 FC), protease inhibitor alpha-1-macroglobulin (4.21 FC), and
actin-binding protein gelsolin (2.35 FC).
3.9 | A focus on amyloid beta (Aβ) 1–42 which is
present in the DCM-mHep7 eluate
Amyloid beta A4 protein (APP) is the precursor protein with many
cleavage products including the Aβ 1–42 peptide and Aβ 1–40 pep-
tide. These are the two major C-terminal variants of the Aβ protein
constituting the majority of Aβ peptides and undergo postsecretory
aggregation and deposition in the Alzheimer's disease (AD) brain.
FIGURE 7 Modified heparin 7 pulldown experiment of CM from MC-Inj (CCM) and MC-Demy (DCM). Condition media collected from control
cultures (UCM), MC-Inj (CCM) and MC-Demy (DCM), was run through a mHep7 column, to select mHep7 binding proteins and identify potential
candidates (6 ml CM used per each pulldown, CM a combination of at least n = 5). (a) Venn diagram depicting the number of candidates both
unique to and shared by each CM. It can be seen that the number of candidates obtained decreased as methods were modified from a
nonquantitative LC/MS to TMT-LC/MS. (b) Graph generated using R package UpsetR, a matrix-based layout showing the intersections of all
three CM data sets. Large symbols indicate the fold increase in shared candidates in DCM and CCM while small red symbols are candidates
increased when compared to control and blue symbols are candidates decreased when compared to control. Circles represent secreted
candidates, with triangles depicting intracellular candidates and squares for candidates that have no reports in the literature a–h are interesting
candidates based on literature searches identified for discussion
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FIGURE 8 Validation of amyloid beta as a candidate for demyelination. (a,b) ELISAs of the mHep7 eluate. Concentration of Aβ 1–42 (p = .0007)
and Aβ 1–40 (p = .0017) is significantly increased in the DCM mHep7-eluate compared to the UCM mHep7 eluate. (c,d) ELISAs of CM after
injury (day 0). There was a large increase in the level of Aβ 1–42 and Aβ 1–40 peptide secretion immediately after demyelination (D0) compared
to the uninjured control (both p < .0001). (e,f ) MC-Demy cultures were treated with mHep7 following demyelination. CM was collected at
26 and 28 DIV (corresponding to days 1 and 3 posttreatment). (e) Graph shows a statistically significant increase in Aβ 1–42 present in DCM
24 hr after mHep7 treatment (D1) compared to untreated control (p = .0003). However, by day 3 posttreatment (D3), there was a significant
reduction in Aβ 1–42 present in the CM following mHep7 treatment (p = .0096). The same pattern was observed with Aβ 1–40 with treatment
leading to an increase in concentration shortly after treatment at D1 (p = .0010), but by D3 there seems to be a significant decrease in the level
of Aβ 1–40 following mHep treatment compared to untreated control (p = .0001). (g–k) Cultures were treated with Aβ 1–42 (1 μM) at 16, 19, and
21 DIV (co-treatments with mHep7 at 100 ng/ml). (g–i) Representative images of control, Aβ treated and Aβ + mHep7 treated cultures at 24 DIV,
immunolabeled with SMI31-red and PLP-green. (j) Quantification of myelination over time showing a significant decrease in developmental
myelination at 24 DIV after Aβ treatment (p = .0082) this is overcome by mHep7 co-treatment (p = .0321). Quantification of neurite density over
time suggests no effect of either treatment on neurite density (data not shown). (k) LDH release cytotoxicity assay demonstrating no statistically
significant effect on cell death at 24 DIV following Aβ treatment or mHep7 co-treatment. Scale bar, 100 μm, error bars SEM (ELISAs n = 3;
technical replicates = 2, cell culture experiments n = 4; technical replicates = 3)
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To investigate the presence of these peptides and validate the
TMT-LC/MS analysis, an ELISA for the 1–42 peptide and 1–40 pep-
tide was carried out on the eluate from the mHep7 column
(Figure 8a,b). This demonstrated that there was a significant
increase in concentration for both Aβ peptides in the DCM eluate
compared to UCM. However, this increase was not observed in the
CCM eluate, suggesting that the increased abundance for the APP
hit in CCM was due to a different cleavage product. This suggests
that the APP cleavage product in the CCM mHep eluate may be
from the nonamyloidogenic pathway. Moreover, the sequence of
peptide fragment identified in the mass spectrometry analysis is a
12 residue peptide corresponding to residues 439–450 of the pre-
cursor protein and represents the soluble product of the initial
cleavage by either α-secretase (nonamyloidogenic pathway) or
β-secretase (amyloidogenic pathway); therefore, the peptide can be
from either pathway.
3.10 | mHep7 treatment modulates Aβ peptide
concentration following demyelination
To confirm the exclusive increase of amyloidogenic peptides in MC-
Demy, ELISAs were performed on the UCM, CCM, and DCM (D0).
This demonstrated a sole increase in the DCM of both Aβ 1–42
(4-fold) and Aβ 1–40 (42-fold) compared to the UCM (Figure 8c,d; p =
.0007 and .0017). As expected we observed a greater abundance of
Aβ1–40 compared with Aβ1–42. This is because Aβ1–40 makes up a
larger proportion of Aβ peptides with the average ratio of 1–40:1–42
being 10:1 (Eckman et al., 1997). There was a large increase in
Aβ1–40 levels immediately after demyelination (D0, Figure 8d) how-
ever 24 hr later (D1, Figure 8f ) this had dropped around 10-fold, we
speculate this is due to the short half-life of this peptide (Farris et al.,
2007). To establish the effect of mHep treatment on Aβ 1–42 and Aβ
1–40 concentration, MC-Demy were treated with mHep7 and CM
collected at days 1 (D1) and 3 (D3) posttreatment. There was a signifi-
cant increase in Aβ 1–42 (1.8-fold) and Aβ 1–40 (9-fold) peptides con-
centration at D1 in the CM following mHep7 treatment compared to
the untreated controls (Figure 8e,f; p = .0003 and .001, respectively).
However, by D3, there seems to be a significant decrease in Aβ 1–42
(0.67-fold) and Aβ 1–40 (0.125-fold) peptides concentration com-
pared to the untreated control (p = .0096 and .0001, respectively).
The results suggest that treatment with mHep7 can modulate the
level of Aβ peptides present in the CM.
3.11 | mHep treatment can overcome Aβ (1–42)
inhibition of myelination
To examine whether Aβ 1–42 peptide has any adverse effect on
developmental myelination, an MC-Dev time course was treated with
Aβ 1–42 peptide (with co-treatment of mHep7). CM was collected
and used in a cytotoxicity assay to establish if treatments induced cell
death. Treatment of MC-Dev cultures with Aβ 1–42 peptide resulted
in a 49% reduction in myelination at 24 DIV (Figure 8g–j; p = .0082).
The absence of any effect on neurite density following treatment
along with the cytotoxicity assay demonstrated that this was not due
to generic cell death (Figure 8k). This inhibitory effect could be
rescued by co-treatment with mHep7 (p = .032). The ELISA data sug-
gests that mHep7 binds both Aβ1–40 and Aβ1–42 peptides reducing
levels present in the cell culture medium after demyelination. Thus,
we hypothesize that mHeps bind to and sequester Aβ1–42 in culture,
preventing its mode of action and so rescuing its inhibition of
myelination.
4 | DISCUSSION
4.1 | Cellular targets for HS: Astrocytes and neurons
Treatment with LS-mHeps showed multiple beneficial outcomes in
our MC-Inj cultures by promoting myelination, increasing neurite
density and outgrowth, and decreasing lesion size. This suggests
these compounds are acting on either multiple cellular targets or
targeting a specific cell type which in turn can mediate several dif-
ferent cellular processes, such as the astrocyte. After CNS injury,
astrocytes become reactive and secrete inflammatory molecules
that modify the environment around the injury or disease (Barnett &
Linington, 2013; Hara et al., 2017; O'Shea, Burda, & Sofroniew,
2017; Williams, Piaton, & Lubetzki, 2007). Moreover, after an injury
to the adult rat brain, there is an overall increase in the quantity of
HSPG around the injury site, as well as an increase in mRNA for
heparan 2-O-sulfotransferase (HS2ST) and subsequently the level of
2-O-sulfated HS (Properzi et al., 2008). Nevertheless, we found little
evidence of reactivity induction following mHep treatment in
scratch astrocyte assays or after Western blotting with GFAP (data
not shown). In addition, changes in sulfation patterns of HSPGs
have many effects on axon growth and guidance. For example,
HS2ST and heparan 6-O-sulfotransferase (HS6ST) knockout mice
have shown multiple navigational errors in their axons, probably due
to disturbance of the guidance effects of slit proteins (Pratt,
Conway, Tian, Price, & Mason, 2006), and genetic manipulations of
syndecan expression in Drosophila showed similar guidance defects
(Johnson et al., 2004). Although information is known about the role
of HSPGs in the development of the CNS, their function in nerve
injury is not yet fully understood (Murakami, Tanaka, Bando, &
Yoshida, 2015). There have been some reports of upregulation of
syndecan-1 and glypicans after injury (Leadbeater et al., 2006) and
evidence that this promotes neurite outgrowth but the mechanism
is not known. It is likely that the HS chains carried by these HSPGs
could be targets for the LS-mHeps.
Our data suggest that the sulfation level or its position on the HS
disaccharide is crucial in regulating cellular function. Using our panel
of mimetics, we found that only the monosulfated forms at the 2-O-
and N-sulfated positions promoted neurite outgrowth. This is in
agreement with a study that used mutants of the Hst-2 gene thereby
reducing 2-O-sulfation on the HS leading to axonal patterning defects
(Kinnunen, Townsend, & Turnbull, 2004). These experiments suggest
that the 2-O-sulfate moiety is involved in neurite outgrowth and path-
finding. However, LS-mHep8 which lacks the 2-O- and 6-O-sulfate
also promotes neurite outgrowth, implying that the reduced sulfation
level of these mHeps may be contributing to the observed outgrowth.
Others have shown that applying HS with different sulfation
682 MCCANNEY ET AL.
modifications disrupts axons guidance in the Xenopus visual system,
with 2-O- and 6-O-sulfated HS having the most marked effects (Irie,
Yates, Turnbull, & Holt, 2002). Therefore, it has been postulated that
there is a sulfation code that regulates axon guidance (Holt & Dickson,
2005). The LS-mHeps could be directly affecting neurite outgrowth,
and astrocytosis through artificially mimicking their interaction with
the growing neurite (Lander, Fujii, Gospodarowicz, & Reichardt, 1982),
or indirectly by altering surrounding cellular behavior, creating a per-
missive environment for outgrowth and re/myelination.
4.2 | HS role in re/myelination
We originally considered that mHeps might regulate growth factors
which act in concert to drive efficient myelination of OPCs. However,
there was no effect of their treatment in developmental myelination
occurring only when cultures were injured. We hypothesise this is
because endogenous HS are sufficient for developmental myelination
but during injury, there are dramatic changes in the extracellular envi-
ronment suggesting that the LS-mHeps may elicit their effects
through interacting with secreted factors present in this aberrant
injury environment.
4.3 | Identification of mHep binding-proteins in CM
from MC-Inj and MC-Demy
To examine the molecular basis for the pro-repair effects in postin-
jury myelinating cultures we aimed to identify heparin-binding pro-
teins in two ways. First, we examined chemokine/cytokine
candidates, and secondly conducted TMT-LC/MS. The chemokine/
cytokine array illustrated major differences in the secretome
between the MC-Demy and MC-Inj. In the former immune-mediated
MC-Demy, inflammatory factors in DCM were more prominent than
in CCM. This suggests that these two different culture conditions
affect remyelination by distinct mechanisms. For example, IL1α,
TNF-α, and C1q (found in DCM, see Figure 6) induce the neurotoxic
A1 astrocyte phenotype (Liddelow et al., 2017) suggesting that in
MC-Demy this astrocyte phenotype may be affecting remyelination,
as previously reported (Nash et al., 2011). Thus, mHeps may be
removing or inhibiting A1 astrocyte inducing factors, therefore pro-
moting remyelination.
Our initial MS analysis was nonquantitative but strongly indicated
pull down heparin-binding proteins as the most significant group pro-
teins (GO enrichment). GO term analysis (data not shown) confirmed
CCM contained many factors involved in neurite outgrowth, guidance
migration, and changes in astrocyte development. In contrast, DCM
contained factors that were related to chemokine signaling and
the immune system. Subsequent TMT LC–MS analysis yielded fold
changes relative to the uninjured control (UCM) and allowed us to
perform direct comparisons between the different CMs with
certainty.
The TMT LC–MS data analysis identified a smaller panel of factors
but with quantitative data from samples analyzed in duplicate. The
reduced sensitivity is a likely consequence of the multiplexing approach,
but the focus on proteins of a higher abundance may remove outliers
and aid in narrowing our list of candidates. As seen with the cytokine
array there was increased expression of immune-mediated factors in
DCM. The reduced list of hits enabled a literature search focused on
secreted proteins with relevance to CNS injury.
TABLE 2 TMT-LC/MS identified candidates: List of complete
candidates that were identified with Mascot scores greater than
30 and fold increase greater than 1.3 in (a) CCM only, (b) DCM only,
and (c) both CCM and DCM
(a) CCM only fold increase
Protein CCM FC Mascot score
Galectin-3-binding protein 2.36 97
Apolipoprotein D 2.04 32
Clusterin 1.88 217
Calsyntenin-3 1.83 91
Carboxylic ester hydrolase 1.7 79
Plakoglobin 1.67 71
Alpha-2-macroglobulin 1.61 232
Complement C2 1.53 240
(b) DCM only fold increase
Protein DCM FC Mascot score
Antithrombin 6.14 151
Inter-alpha-trypsin inhibitor 5.66 49
Complement component 4A 4.66 60
Ac2-120 4.6 67
Apolipoprotein B-100 4.57 90
Alpha-1-macroglobulin 4.21 49
Igh-6 protein 4.13 75
Thrombospondin 1 4.07 240
Inter-alpha trypsin inhibitor 3.2 220
Complement C5 2.77 29
Gelsolin 2.35 284
Liprin-alpha-3 2.34 34
Plasminogen activator inh 1 1.79 228
Alpha-2 antiplasmin 1.72 375
Complement C1q subunit C 1.68 48
Glia-derived nexin 1.67 76
Aa1018 1.48 166
Periostin 1.45 59
Tenascin C 1.44 97
Complement C3 1.43 234
Heat shock cognate 71 kDa 1.4 54
Spondin-1 1.4 62
Noelin 1.32 61
(c) CCM and DCM fold increase
Protein
CCM
FC
DCM
FC
Mascot
score
Growth horm releasing horm R 327 136.5 30
Amyloid beta A4 protein 5.76 2.01 88
Tubulin alpha-1A chain 2.98 2.13 129
Aplp1 protein 2.75 1.47 29
Fruct-bisphosphate aldolase A 2.48 2.63 100
Complement inhibitory factor H 1.32 1.4 43
Xylosyltransferase 1 1.66 2.11 36
Candidates that are secreted and of interest in these cultures are
highlighted in bold and reflect those indicated in Figure 7b
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4.4 | Factors found in CCM
Table 2a illustrates candidates isolated from CCM that were
expressed at greater than 1.3-fold increase when compared to UCM.
A2M, a broad spectrum proteinase inhibitor and a carrier of growth
factors was increased in CCM. It has neuromodulatory activities
(Wolf & Gonias, 1994) and has been demonstrated as a marker of
neuronal injury and associated with preclinical AD (Varma et al.,
2017). Apolipoprotein D (ApoD) is a secreted glycoprotein with many
roles within lipid transport, detected in neurons, astrocytes, and oligo-
dendrocytes (Ong et al., 1999). It has been associated with neurologi-
cal disorders (multiple sclerosis [MS] and AD), other inflammatory
diseases of the CNS and nerve injury (Li et al., 2015; Reindl et al.,
2001). Interestingly levels were not above threshold in MC-Demy,
suggesting a nerve damage component to its upregulated expression.
Clusterin (CLU) a small heat shock protein that can act as a molec-
ular chaperone protein was also upregulated. CLU like ApoD, has been
implicated in ameliorating oxidative stress in neurodegenerative dis-
eases and may be involved in the death of damaged neurons
(Törnqvist, Liu, Aldskogius, Holst, & Svensson, 1996). It has been iden-
tified in the cerebrospinal fluid (CSF) of patients with MS (van Luijn
et al., 2016) and AD (Matsuoka et al., 2001; Wojtas et al., 2017) and
thought to act as a carrier of several proteins across the BBB and CSF
barrier including amyloid-β (Aβ) (Ghiso et al., 1993; Zlokovic et al.,
1996). It has been suggested that CLU directly interacts with Aβ,
thereby regulating its clearance from the brain (Bell et al., 2007). Amy-
loid precursor protein (APP), which was also secreted in CCM and
DCM, is known to be upregulated during axonal injury in MS
(Ferguson, Matyszak, Esiri, & Perry, 1997), and CLU may clear it and
thereby prevent aggregation of Aβ. It was also interesting that RAGE
was upregulated in the cytokine array as it is thought to play a role in
the peripheral re-entry of Aβ into the brain (Deane et al., 2003).
4.5 | Factors found in DCM
Table 2b shows there were more candidates pulled down exclusively
in DCM compared to CCM. Several have already been implicated in
CNS injury, for example tenascin C (TnC), a glycoprotein synthesized
by astrocytes and secreted into the ECM. Increased expression of
TnC has been implicated after demyelination in vivo (Zhao, Fancy,
Franklin, & ffrench-Constant, 2009) and been shown to inhibit OPC
differentiation in vitro both directly and indirectly through astrocytes
(Czopka, von Holst, ffrench-Constant, & Faissner, 2010; Nash et al.,
2011). Moreover, knockout of TnC resulted in a favorable outcome
on ADs pathology in vivo (Xie et al., 2013). Another ECM glycoprotein
thrombospondin 1 (TSP-1) also appeared to have increased abun-
dance in DCM. TSP-1 interacts with Neuroligin 1 to accelerate synap-
togenesis of hippocampal neurons (Xu, Xiao, & Xia, 2010) but also
reported to promote OPC migration (Scott-Drew & ffrench-Con-
stant, 1997).
Gelsolin, an actin regulatory factor was identified in DCM. Mice
lacking gelsolin, display a delayed remyelination after PNS crush inju-
ries, presumed due to gelsolin recruiting macrophages to the injury
site (Gonçalves et al., 2010). Moreover, gelsolin knockout mice had
wrapping defects in the CNS, (Zuchero et al., 2015). This implies
gelsolin might have a dual role after injury, firstly through the recruit-
ment of immune cells to clear debris and secondly facilitating oligo-
dendrocyte axon ensheathment.
4.6 | Candidate factors identified in both DCM
and CCM
In Table 2c, it can be seen that a few candidates were upregulated in
both CCM and DCM and therefore may relate to promoting myelina-
tion. For example, growth hormone releasing hormone receptor has
been detected in the CNS, and its ligand activity promotes the secre-
tion of insulin-like growth factor (IGF-1, Zhao et al., 2008), a known
mitogen for OPCs and an important regulator of brain development,
maintenance and neurogenesis (Aberg, 2010). Moreover, APP was
identified in both CMs. HS has been shown to interact with Aβ pep-
tides and thus been implicated in facilitating Aβ cytotoxicity and accel-
erating amyloid fibril formation (Castillo, Ngo, Cummings, Wight, &
Snow, 1997; Sandwall et al., 2010). Additionally, infusion with Aβ and
HS into rat brains resulted in increased amyloidosis compared to Aβ
alone (Snow, Sekiguchi, Nochlin, Kalaria, & Kimata, 1994). This sug-
gests that endogenous HS somewhat aids Aβ aggregation pathology.
Aβ has been shown to be secreted in excess following traumatic injury
(Gentleman, Nash, Sweeting, Graham, & Roberts, 1993) and MS
lesions (Pajoohesh-Ganji et al., 2014). Although not understood in
these pathological conditions Aβ has been reported to have negative
correlation with functional outcome and induce microglia activation,
inflammation, and neuronal cell death (Matsuoka et al., 2001).
Due to the detection of Aβ in MC-Inj and MC-Demy and its
known role in CNS pathology we decided to focus more on its func-
tion and interaction with mHeps in these cultures. Since APP has
numerous different fragment peptides, it was important to determine
the peptides identified in the TMT/LC–MS. ELISAs of the mHep7 elu-
ates and CMs suggests that after demyelination in MC-Demy Aβ pep-
tides (1–40/1–42) are secreted, and that the degradation of these
peptides is modulated directly by mHep treatment. Previously, it has
been demonstrated that treatment with Aβ 1–42 inhibits OPC differ-
entiation (Horiuchi et al., 2012), in this study, we developed this fur-
ther showing that the effect was present at the level of myelination
and could be rescued through mHep co-treatment. However, it
appears that the APP detected in the CCM mHep7 eluate TMT-LC
analysis was not Aβ 1–40 or 1–42 peptides, suggesting it was the P3
peptide from the nonamyloidgenic pathway. This peptide is the equiv-
alent of Aβ 17–40/42, although this fragment does not assemble into
soluble oligomers, it does possess cellular toxic properties (Dulin et al.,
2008; Wei, Norton, Wang, & Kusiak, 2002). Hence the P3 peptide
could be a mHep7 modulated negative injury factor secreted after
MC-Inj. As Aβ peptides have been reported in both neurodegenera-
tion and traumatic injury, with studies demonstrating the therapeutic
benefits of targeting BACE-1 in AD (Scholefield et al., 2003). This Aβ
peptides could be a valuable target for mHep7 and the action of
sequestering or inhibiting aggregation, could promote neurite out-
growth and myelination in MC-Inj and MC-Demy.
In summary, the present study has demonstrated beneficial
effects of LS-mHeps on repair in models of CNS damage specifically
promoting neurite outgrowth and myelination by modifying the
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properties of secreted factors generated after injury. Our data has
identified multiple protein candidates for mediating these effects and
thus plausible underlying mechanisms. Moreover, this illustrates the
complexity of mediating repair and highlights that therapeutics need
to target many factors, as seen by LS-mHeps. Furthermore, we show
Aβ peptides can play a role in demyelination. Finally, based on the pro-
tein hits and the relation of some of these proteins to other neurologi-
cal disease such as AD, these novel compounds could also have
therapeutic potential in other neurological disorders.
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